LMF1
Basic information
Region (hg38): 16:853634-981318
Previous symbols: [ "C16orf26", "TMEM112" ]
Links
Transcripts
Transcript IDs starting with ENST are treated as Ensembl, all others as RefSeq. Showing 4 of 18.
| Transcript ID | Protein ID | Coding exons | MANE Select | MANE Plus Clinical |
|---|---|---|---|---|
ENST00000262301.16 | ENSP00000262301.12 | 11 | yes | - |
ENST00000543238.5 | ENSP00000437418.1 | 7 | - | - |
ENST00000545827.6 | ENSP00000443820.2 | 3 | - | - |
ENST00000562226.5 | ENSP00000455833.1 | 4 | - | - |
Phenotypes
GenCC
Source:
- lipase deficiency, combined (Moderate), mode of inheritance: AR
- lipase deficiency, combined (Strong), mode of inheritance: AR
- lipase deficiency, combined (Strong), mode of inheritance: AR
- lipase deficiency, combined (Supportive), mode of inheritance: AR
Clinical Genomic Database
Source:
| Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
|---|---|---|---|---|---|
| Combined lipase deficiency | AR | Cardiovascular; Endocrine; Gastrointestinal | Individuals may present with severe hypertryglceridemia, with findings including gastrointestinal manifestations (abdominal pain, emesis, recurrent pancreatitis, hepatosplenomegaly), as well as eruptive xanthomata and lipemia retinalis, and dietary measures (fat restriction) and medical treatment (eg, gemfibrozil, omega-3 fatty acid supplementation) can be beneficial; Individuals may also manifest with diabetes mellitus, which can benefit from standard treatment (and which may also help with other manifestations) | Cardiovascular; Endocrine; Gastrointestinal | 17994020; 19820022 |
ClinVar
This is a list of variants' phenotypes submitted to
- Cardiovascular_phenotype (521 variants)
- not_provided (323 variants)
- Lipase_deficiency,_combined (36 variants)
- not_specified (34 variants)
- LMF1-related_disorder (31 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the LMF1 gene is commonly pathogenic or not. These statistics are base on transcript: NM_000022773.4. Only rare variants are included in the table.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUSVUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 4 | 218 | 2 | 224 | ||
| missense | 3 | 300 | 42 | 6 | 351 | |
| nonsense | 6 | 10 | 1 | 17 | ||
| start loss | 0 | |||||
| frameshift | 7 | 5 | 12 | |||
| splice donor/acceptor (+/-2bp) | 1 | 2 | 3 | 6 | ||
| Total | 14 | 20 | 308 | 260 | 8 |
Highest pathogenic variant AF is 0.000060750102
GnomAD
Source:
| Gene | Type | Bio Type | Transcript | Coding Exons | Length |
|---|---|---|---|---|---|
| LMF1 | protein_coding | protein_coding | ENST00000262301 | 11 | 127685 |
| pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
|---|---|---|---|---|---|---|
| 124553 | 0 | 113 | 124666 | 0.000453 |
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
|---|---|---|---|---|---|---|
| Missense | -1.79 | 446 | 351 | 1.27 | 0.0000225 | 3630 |
| Missense in Polyphen | 170 | 139.91 | 1.2151 | 1431 | ||
| Synonymous | -2.66 | 194 | 152 | 1.27 | 0.0000104 | 1140 |
| Loss of Function | 0.442 | 25 | 27.5 | 0.909 | 0.00000143 | 259 |
LoF frequencies by population
| Ethnicity | Sum of pLOFs | p |
|---|---|---|
| African & African-American | 0.000902 | 0.000889 |
| Ashkenazi Jewish | 0.00 | 0.00 |
| East Asian | 0.000671 | 0.000668 |
| Finnish | 0.000145 | 0.000139 |
| European (Non-Finnish) | 0.000451 | 0.000443 |
| Middle Eastern | 0.000671 | 0.000668 |
| South Asian | 0.000690 | 0.000686 |
| Other | 0.000906 | 0.000826 |
dbNSFP
Source:
- Function
- FUNCTION: Involved in the maturation of specific proteins in the endoplasmic reticulum. Required for maturation and transport of active lipoprotein lipase (LPL) through the secretory pathway. Each LMF1 molecule chaperones 50 or more molecules of LPL. {ECO:0000250|UniProtKB:Q3U3R4, ECO:0000269|PubMed:24909692}.;
- Disease
- DISEASE: Combined lipase deficiency (CLD) [MIM:246650]: Characterized by repeated episodes of pancreatitis, tuberous xanthomas and lipodystrophy and is caused by deficiency of both lipoprotein lipase (LPL) and hepatic triglyceride lipase (HTGL). {ECO:0000269|PubMed:17994020}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
- Pathway
- Transport of small molecules;Assembly of active LPL and LIPC lipase complexes;Plasma lipoprotein assembly, remodeling, and clearance;Plasma lipoprotein remodeling
(Consensus)
Recessive Scores
- pRec
- 0.118
Intolerance Scores
- loftool
- 0.865
- rvis_EVS
- 1.23
- rvis_percentile_EVS
- 93.26
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- N
- gene_indispensability_score
- 0.444
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |
Gene ontology
- Biological process
- triglyceride metabolic process;endoplasmic reticulum to Golgi vesicle-mediated transport;protein secretion;protein glycosylation in Golgi;chylomicron remnant clearance;regulation of lipoprotein lipase activity;positive regulation of lipoprotein lipase activity;protein maturation;regulation of cholesterol metabolic process;regulation of triglyceride metabolic process
- Cellular component
- endoplasmic reticulum membrane;Golgi apparatus;integral component of membrane
- Molecular function